study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
INFL-INF11-01,2021,randomized controlled trial,SMD,-0.231,-0.3961,-0.0659,75,81,mixed,10.1234/infl-inf11-01,inflammation-journal-01,joint_pain,Adults with joint pain concerns,Transient headache,9
INFL-INF11-02,2012,randomized controlled trial,SMD,-0.2256,-0.3732,-0.078,88,96,low,10.1234/infl-inf11-02,inflammation-journal-02,joint_pain,Adults with joint pain concerns,Mild GI discomfort,13
INFL-INF11-03,2017,randomized controlled trial,SMD,-0.2202,-0.3502,-0.0902,71,81,low,10.1234/infl-inf11-03,inflammation-journal-03,joint_pain,Adults with joint pain concerns,None reported,12
